These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 12030199)

  • 1. Researchers find easy way to predict outcomes.
    AIDS Alert; 2002 Apr; 17(4):45-6. PubMed ID: 12030199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Summaries for patients. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and patient outcomes.
    Ann Intern Med; 2007 Apr; 146(8):I28. PubMed ID: 17438312
    [No Abstract]   [Full Text] [Related]  

  • 3. A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV.
    Grossberg R; Zhang Y; Gross R
    J Clin Epidemiol; 2004 Oct; 57(10):1107-10. PubMed ID: 15528063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda.
    Spacek LA; Shihab HM; Kamya MR; Mwesigire D; Ronald A; Mayanja H; Moore RD; Bates M; Quinn TC
    Clin Infect Dis; 2006 Jan; 42(2):252-9. PubMed ID: 16355337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-HIV agents. What makes a viral load blip?
    TreatmentUpdate; 2008 Jan; 20(1):4. PubMed ID: 18320693
    [No Abstract]   [Full Text] [Related]  

  • 7. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
    Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV viral load monitoring in resource-limited regions: optional or necessary?
    Calmy A; Ford N; Hirschel B; Reynolds SJ; Lynen L; Goemaere E; Garcia de la Vega F; Perrin L; Rodriguez W
    Clin Infect Dis; 2007 Jan; 44(1):128-34. PubMed ID: 17143828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
    Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M
    HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting and monitoring antiretroviral adherence.
    Gross R
    LDI Issue Brief; 2007; 13(2):1-4. PubMed ID: 18354853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients.
    Van Laethem K; De Luca A; Antinori A; Cingolani A; Perna CF; Vandamme AM
    Antivir Ther; 2002 Jun; 7(2):123-9. PubMed ID: 12212924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and tolerability of a once-daily amprenavir/ritonavir-containing highly active antiretroviral therapy regimen in antiretroviral-naïve patients at risk for nonadherence: 48-week results after 24 weeks of directly observed therapy.
    Jayaweera DT; Kolber MA; Brill M; Tanner T; Campo R; Rodriguez A; Chu HM; Garg V
    HIV Med; 2004 Sep; 5(5):364-70. PubMed ID: 15369512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Running with scissors: using antiretroviral therapy without monitoring viral load.
    Smith DM; Schooley RT
    Clin Infect Dis; 2008 May; 46(10):1598-600. PubMed ID: 18419496
    [No Abstract]   [Full Text] [Related]  

  • 14. Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients.
    Maggiolo F; Ripamonti D; Gregis G; Quinzan G; Callegaro A; Arici C; Ravasio L; Suter F
    Antivir Ther; 2003 Aug; 8(4):339-46. PubMed ID: 14518703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of a World Health Organization first-line regimen (stavudine/lamivudine/nevirapine) in antiretroviral-naïve individuals in a Western setting.
    Tam LW; Hogg RS; Yip B; Montaner JS; Harrigan PR; Brumme CJ
    HIV Med; 2007 Jul; 8(5):267-70. PubMed ID: 17561871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Viral loads in pediatric HIV patients with antiretroviral treatment].
    Porto-Espinoza L; Moronta R; Cuadra-Sánchez C; Callejas-Valero D; Costa-León L; Monsalve-Castillo F; Bernardoni C; Estévez J
    Rev Med Chil; 2008 Aug; 136(8):1021-6. PubMed ID: 18949186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?
    Reekie J; Mocroft A; Sambatakou H; Machala L; Chiesi A; van Lunzen J; Clumeck N; Kirk O; Gazzard B; Lundgren JD;
    AIDS; 2008 Nov; 22(17):2381-90. PubMed ID: 18981778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching.
    Elliott JH; Lynen L; Calmy A; De Luca A; Shafer RW; Zolfo M; Clotet B; Huffam S; Boucher CA; Cooper DA; Schapiro JM
    AIDS; 2008 Oct; 22(16):2053-67. PubMed ID: 18753937
    [No Abstract]   [Full Text] [Related]  

  • 20. Designing and interpreting HIV noninferiority trials in naive and experienced patients.
    Hill A; Sabin C
    AIDS; 2008 May; 22(8):913-21. PubMed ID: 18453850
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.